On November 14 2014 the FDA announced the approval of Lemtrada (alemtuzumab) as a treatment for patients with relapsing forms of multiple sclerosis (MS) who have previously failed two other drugs. This decision marked the culmination of a long and tortuous path in the history of the drug. As one of the oldest therapeutic monoclonal drugs, the development of Lemtrada provides important insights into the long and complex process involved in drug discovery and development.
Some idea of the trials and tribulations scientists and patients went through to get the drug to the clinic can be seen in the the exhibition ‘The life Story of a Biotechnology drug: Alemtuzumab’. Put together by Dr Lara Marks, a research affiliate at SSHM, this exhibition follows first hand the difficulties involved in translating science from the benchside to the clinic. Providing a rich collection of historical photographs, documents and interview material, the exhibition opens up to the visitor the many different facets involved in drug development. It provides a powerful insight into the complexities faced by the host of actors involved in drug development, all the way from academic scientists and industry experts, clinicians through to patients. As this exhibition shows, none of these actors can escape the pressures of the world’s financial market or the hurdles involved in regulatory approval.
To view the exhibition go to: http://www.whatisbiotechnology.org/exhibitions/campath
For inquiries contact Dr Lara Marks: email@example.com